Roche and Hamilton Introduce New Automated DNA Sample Enrichment Platform for GS Junior Sequencing Instruments
Roche and Hamilton Robotics jointly announced the introduction of a new, integrated platform enabling automated DNA sample enrichment for Roches 454 GS Junior
Penzberg, Germany; Branford, Connecticut and Reno, Nevada, USA, February 28, 2013 / B3C newswire / - Today Roche and Hamilton Robotics jointly announced the introduction of a new, integrated platform enabling automated DNA sample enrichment for Roche’s 454 GS Junior
sequencer. The platform builds on the integration of Roche’s REM e System with Hamilton’s Microlab® NIMBUS NGS workstation, resulting in reduced hands-on time, minimized operational variability and more consistent results.
“This new integrated platform will replace about four hours of laborious manual work,” said Thomas Schinecker, head of 454 Life Sciences “It is a true walkaway solution, offering an economical, convenient, compact enrichment procedure for all our GS Junior customers. We look forward to continuing our collaboration with Hamilton to develop more innovative, automated solutions for our GS Junior System.”
The new platform has been fully tested and validated to automate the emPCR breaking, bead enrichment and sequence primer annealing steps in the GS Junior sample preparation workflow. Dedicated software with a graphical user interface (GUI) provides easy automation setup and simple user control.
“The Hamilton NIMBUS NGS Systems are built to speed the liquid handling process by using advanced robotic pipetting technologies,” said Dr. Jose Carle, Vice President, Hamilton Robotics. “With Roche we’ve intentionally kept the systems easy to use, affordable and smaller than conventional systems, thus putting the power of high-throughput genetic analysis and discovery directly into researchers' hands.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance